Bradmer Announces Second Quarter 2016 Financial Results
(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 08/08/16 -- Bradmer Pharmaceuticals Inc. ("Bradmer" or the "Company") (NEX: BMR.H) today announced its second quarter 2016 financial results.
Financial Results
Amounts in US dollars, unless specified otherwise, and results prepared in accordance with International Financial Reporting Standards ("IFRS").
For the three months ended June 30, 2016, we recorded a net loss of $42,000 or $0.002 per common share based on the weighted average outstanding shares of 19,659,726 during the three month period, compared to a net loss of $59,000 or $0.003 per common share for the quarter ended June 30, 2015 based on the weighted average outstanding shares of 19,659,726.
General and administrative expenses were $42,000 in the three months ended June 30, 2016 compared to $53,000 in the same quarter of the prior year. Major expenses in 2016 consisted of legal fees of $21,000, consulting fees of $14,000, audit fees of $2,800 and directors'' and officers'' liability insurance premiums of $2,500. Expenses in 2015 consisted of a work fee from WCM Capital of $20,000, consulting fees of $14,000, legal fees of $7,000, transfer agent and stock exchange listing fees of $4,000 and directors'' and officers'' liability insurance premiums of $3,000.
For the six months ended June 30, 2016, we recorded a net loss of $94,000 or $0.005 per common share based on the weighted average outstanding shares of 19,659,726 during the six month period, compared to a net loss of $56,000 or $0.003 per common share for the six months ended June 30, 2015 based on the weighted average outstanding shares of 19,659,726.
General and administrative expenses were $69,000 in the six months ended June 30, 2016 compared to $85,000 in the same period of the prior year. Major expenses in 2016 consisted of consulting fees of $27,000, legal fees of $21,000, transfer agent and stock exchange listing fees of $9,000 and insurance premiums of $5,000. Expenses in 2015 consisted of a work fee from WCM Capital of $20,000, consulting fees of $30,000, legal fees of $16,000, transfer agent and stock exchange listing fees of $5,000 and insurance premiums of $6,000.
Bradmer''s operational activities for the six months ended June 30, 2016 were financed by cash on hand. At June 30, 2016, we had working capital of $436,000, compared to $500,000 at December 31, 2015. We had available cash of $455,000 (CDN $592,000) as at June 30, 2016, compared to cash of $521,000 (CDN $721,000) as at December 31, 2015. The $65,400 decrease in cash was due to the $94,000 net loss offset by the $30,000 of foreign currency translation adjustments.
As at August 8 and June 30, 2016, the Company had 19,659,726 common shares and options to purchase 1,950,000 common shares outstanding.
Additional information about Bradmer, including the MD&A and financial results may be found on SEDAR at .
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Bradmer''s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.
Except for historical information, this news release may contain forward-looking statements, which reflect the Company''s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company''s ongoing quarterly and annual reporting.
Contacts:
Bradmer Pharmaceuticals Inc.
Paul Van Damme
Chief Financial Officer
1.416.847.6905
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 08.08.2016 - 12:10 Uhr
Sprache: Deutsch
News-ID 1451332
Anzahl Zeichen: 7657
contact information:
Contact person:
Town:
TORONTO, ONTARIO
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 213 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bradmer Announces Second Quarter 2016 Financial Results
"
steht unter der journalistisch-redaktionellen Verantwortung von
Bradmer Pharmaceuticals Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
